Enovis Corporation — Form 10-Q Summary
Business context and reporting period
Enovis is a medical technology company operating through two reportable segments: Prevention & Recovery and Reconstructive. The filing covers the three and six months ended June 30, 2023, compared with July 1, 2022. The statements are unaudited and presented under U.S. GAAP.
Key financial metrics
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $428.5 million | $395.1 million | $834.7 million | $770.6 million |
| Gross profit / margin | $248.4 million / 58.0% | $215.9 million / 54.6% | $483.4 million / 57.9% | $421.8 million / 54.7% |
| Operating income (loss) | $(14.5) million / (3.4)% | $5.6 million / 1.4% | $(39.5) million / (4.7)% | $(25.1) million / (3.3)% |
| Net income (loss) attributable to Enovis | $(10.0) million | $76.9 million | $(33.3) million | $91.9 million |
| Adjusted EBITDA | $65.7 million / 15.3% | $56.2 million / 14.2% | $122.1 million / 14.6% | $103.9 million / 13.5% |
| Diluted EPS | $(0.18) | $1.41 | $(0.61) | $1.69 |
- Operating cash flow was $35.6 million for the first six months of 2023 versus $(39.3) million in the prior-year period.
- Capital expenditures and intangible purchases were $67.2 million; acquisitions and investments used $98.7 million.
- Cash and cash equivalents were $32.5 million at June 30, 2023, up from $24.3 million at December 31, 2022.
- Total debt was $400.0 million, all classified as long-term, compared with $259.3 million at year-end 2022. The weighted-average borrowing rate was 6.32%, and $500.0 million remained available under the $900.0 million revolver.
- The company reported compliance with its debt covenants, including a maximum total leverage ratio of 3.75:1.00 and minimum interest coverage ratio of 3.00:1.00.
Material changes versus the prior comparable period
- Sales increased 8.4% in Q2 and 8.3% year to date. Existing businesses contributed 7.9% and 8.6%, respectively; acquisitions contributed 0.2% and 0.3%; foreign currency contributed 0.3% in Q2 but reduced year-to-date sales by 0.6%.
- Prevention & Recovery sales increased 3.7% in Q2 and 3.1% year to date. Reconstructive sales increased 18.1% and 18.5%, respectively.
- Gross margin expanded by 340 basis points in Q2 and 320 basis points year to date, reflecting volume, pricing, mix, operating leverage, and lower inventory step-up amortization, partly offset by inflation and foreign exchange effects.
- Adjusted EBITDA increased 16.9% in Q2 and 17.5% year to date, with margin expansion of 110 and 110 basis points, respectively.
- GAAP earnings declined sharply because the 2022 periods included a $135.5 million unrealized gain on the ESAB investment and a $33.0 million insurance settlement gain. The prior year also included $20.1 million of debt extinguishment charges.
- Novastep was acquired on June 28, 2023 for approximately $96.9 million net of cash received, adding minimally invasive foot and ankle products. The company also closed the $28.0 million SEAL external fixation product-line acquisition on July 20, 2023, after the reporting date.
Outlook, commentary, risks, and unusual items
Management stated that available liquidity is adequate to fund operations for the next twelve months. The filing does not provide a clear quantitative revenue, earnings, or margin guidance range.
- Management attributes growth to market strength, higher volumes, pricing actions, product mix, and operating leverage, particularly in Reconstructive.
- Recent acquisitions were modestly dilutive to current margins but are expected by management to become accretive in future years.
- Restructuring and other charges were $6.4 million year to date. MDR and other regulatory costs were $16.8 million, strategic transaction costs were $17.1 million, and stock-based compensation was $15.8 million.
- Discontinued operations generated $4.8 million of Q2 income and $4.5 million year-to-date income, including tax benefits related to released uncertain tax positions and a tax indemnification release. These items are not indicative of ongoing operating performance.
- Key risks include acquisition integration and financing, leverage and covenant restrictions, foreign exchange, inflation and supply-chain pressures, manufacturing disruption, regulatory and product liability exposure, reimbursement and healthcare policy changes, cybersecurity, intellectual property, goodwill or intangible impairment, and litigation or indemnification obligations related to the ESAB separation.
- Pending legal and regulatory matters arise in the ordinary course; management does not expect them to have a material adverse effect, but the filing cautions that adverse outcomes could be material.
Important facts for investors to verify
- Reconcile reported GAAP losses with Adjusted EBITDA and assess the recurring nature of MDR, strategic transaction, restructuring, acquisition-amortization, and stock-compensation adjustments.
- Monitor leverage, variable-rate debt costs, the $500.0 million revolver availability, and compliance with the 3.75:1.00 leverage covenant before its step-down to 3.50:1.00 in 2024.
- Evaluate whether Reconstructive growth and the Novastep and SEAL acquisitions deliver the expected revenue synergies and future margin accretion.
- Assess working-capital requirements, including inventories of $453.9 million and receivables of $299.0 million, relative to operating cash generation.
- Review the impact of foreign currency movements, including the $450.0 million U.S.-dollar notional cross-currency swaps and related accumulated other comprehensive loss.
- Confirm the ultimate amount and timing of contingent consideration liabilities, reported at $21.6 million, and any continuing obligations or tax indemnification matters related to the ESAB separation.